Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency

Basit Öğe Kaydı
dc.contributor.authorKiykim A.
dc.contributor.authorOgulur I.
dc.contributor.authorDursun E.
dc.contributor.authorCharbonnier L.M.
dc.contributor.authorNain E.
dc.contributor.authorCekic S.
dc.contributor.authorDogruel D.
dc.contributor.authorKaraca N.E.
dc.contributor.authorCogurlu M.T.
dc.contributor.authorBilir O.A.
dc.contributor.authorCansever M.
dc.contributor.authorKapakli H.
dc.contributor.authorBaser D.
dc.contributor.authorKasap N.
dc.contributor.authorKutlug S.
dc.contributor.authorAltintas D.U.
dc.contributor.authorAl-Shaibi A.
dc.contributor.authorAgrebi N.
dc.contributor.authorKara M.
dc.contributor.authorGuven A.
dc.contributor.authorSomer A.
dc.contributor.authorAydogmus C.
dc.contributor.authorAyaz N.A.
dc.contributor.authorMetin A.
dc.contributor.authorAydogan M.
dc.contributor.authorUncuoglu A.
dc.contributor.authorPatiroglu T.
dc.contributor.authorYildiran A.
dc.contributor.authorGuner S.N.
dc.contributor.authorKeles S.
dc.contributor.authorReisli I.
dc.contributor.authorAksu G.
dc.contributor.authorKutukculer N.
dc.contributor.authorKilic S.S.
dc.contributor.authorYilmaz M.
dc.contributor.authorKarakoc-Aydiner E.
dc.contributor.authorLo B.
dc.contributor.authorOzen A.
dc.contributor.authorChatila T.A.
dc.contributor.authorBaris S.
dc.date.accessioned2019-10-26T21:14:07Z
dc.date.available2019-10-26T21:14:07Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte–associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established. Objective: To determine the clinical and immunologic features of LRBA deficiency and long-term efficacy of abatacept treatment in controlling the different disease manifestations. Methods: Twenty-two LRBA-deficient patients were recruited from different immunology centers and followed prospectively. Eighteen patients on abatacept were evaluated every 3 months for long-term clinical and immunologic responses. LRBA expression, lymphocyte subpopulations, and circulating T follicular helper cells were determined by flow cytometry. Results: The mean age of the patients was 13.4 ± 7.9 years, and the follow-up period was 3.4 ± 2.3 years. Recurrent infections (n = 19 [86.4%]), immune dysregulation (n = 18 [81.8%]), and lymphoproliferation (n = 16 [72.7%]) were common clinical features. The long-term benefits of abatacept in 16 patients were demonstrated by complete control of lymphoproliferation and chronic diarrhea followed by immune dysregulation, most notably autoimmune cytopenias. Weekly or every other week administration of abatacept gave better disease control compared with every 4 weeks. There were no serious side effects related to the abatacept therapy. Circulating T follicular helper cell frequencies were found to be a reliable biomarker of disease activity, which decreased on abatacept therapy in most subjects. However, high circulating T follicular helper cell frequencies persisted in 2 patients who had a more severe disease phenotype that was relatively resistant to abatacept therapy. Conclusions: Long-term abatacept therapy is effective in most patients with LRBA deficiency. © 2019 American Academy of Allergy, Asthma & Immunologyen_US
dc.identifier.doi10.1016/j.jaip.2019.06.011
dc.identifier.issn2213-2198
dc.identifier.issn2213-2198en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2019.06.011
dc.identifier.urihttps://hdl.handle.net/11454/15839
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAmerican Academy of Allergy, Asthma and Immunologyen_US
dc.relation.ispartofJournal of Allergy and Clinical Immunology: In Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbatacepten_US
dc.subjectAutoimmunityen_US
dc.subjectImmune dysregulationen_US
dc.subjectLPS-responsive beige-like anchoren_US
dc.subjectT follicular helper cellsen_US
dc.titleAbatacept as a Long-Term Targeted Therapy for LRBA Deficiencyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu